Results 71 to 80 of about 4,947,478 (390)

Embolization in an adrenocortical carcinoma as palliative therapy [PDF]

, 1999
Background: With an annual incidence of 0.2% of new cases per 100,000 inhabitants, adrenocortical carcinoma is rare. In advanced tumor only palliative treatment modalities are practicable. Because of scarcity of the tumor, standard treatment has not been
Braunschweig, R., Forstpointner, Roswitha, Kühl, M., Lang, N., Meissner, H., Schalhorn, Andreas   +5 more
core   +1 more source

Integrated Genomic Analyses of Ovarian Carcinoma

Nature, 2011
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter ...
D. Bell, A. Berchuck, M. Birrer, J. Chien, D. Cramer, F. Dao, R. Dhir, P. Disaia, H. Gabra, Pat Glenn, A. Godwin, J. Gross, L. Hartmann, M. Huang, D. Huntsman, M. Iacocca, M. Imieliński, S. Kalloger, B. Karlan, D. Levine, G. Mills, C. Morrison, D. Mutch, Narciso Olvera, S. Orsulic, K. Park, N. Petrelli, B. Rabeno, J. Rader, B. Sikic, K. Smith-McCune, A. Sood, D. Bowtell, R. Penny, J. Testa, K. Chang, H. Dinh, J. Drummond, G. Fowler, P. Gunaratne, A. Hawes, C. Kovar, L. Lewis, M. Morgan, I. Newsham, J. Santibanez, J. Reid, L. Treviño, Y. Wu, M. Wang, D. Muzny, D. Wheeler, R. Gibbs, G. Getz, M. Lawrence, K. Cibulskis, A. Sivachenko, C. Sougnez, Douglas Voet, Jane Wilkinson, Toby Bloom, K. Ardlie, T. Fennell, J. Baldwin, S. Gabriel, E. Lander, L. Ding, R. Fulton, D. Koboldt, M. McLellan, T. Wylie, Jason R. Walker, M. O'Laughlin, D. Dooling, L. Fulton, R. Abbott, N. Dees, Q. Zhang, C. Kandoth, M. Wendl, W. Schierding, D. Shen, C. Harris, H. Schmidt, Joelle Kalicki, K. Delehaunty, C. Fronick, Ryan T. Demeter, L. Cook, J. Wallis, L. Lin, V. Magrini, J. Hodges, James M. Eldred, S. M. Smith, C. Pohl, Fabio Vandin, Benjamin J. Raphael, G. Weinstock, E. Mardis, R. Wilson, M. Meyerson, W. Winckler, R. Verhaak, Suzie Carter, C. Mermel, G. Saksena, H. Nguyen, R. Onofrio, D. Hubbard, S. Gupta, A. Crenshaw, A. Ramos, L. Chin, A. Protopopov, Juinhua Zhang, T. Kim, I. Perna, Y. Xiao, Hailei Zhang, G. Ren, N. Sathiamoorthy, R. Park, E. Lee, P. Park, R. Kucherlapati, D. Absher, L. Waite, G. Sherlock, J. Brooks, Jun Li, Jin Xu, R. Myers, P. Laird, L. Cope, J. Herman, Hui Shen, D. Weisenberger, H. Noushmehr, F. Pan, T. Triche, B. Berman, D. V. Berg, J. Buckley, S. Baylin, P. Spellman, E. Purdom, P. Neuvial, H. Bengtsson, L. Jakkula, S. Durinck, J. Han, S. Dorton, H. Marr, Y. Choi, V. Wang, Ninghai Wang, J. Ngai, J. Conboy, B. Parvin, H. Feiler, T. Speed, J. Gray, N. Socci, Yanke Liang, B. Taylor, N. Schultz, L. Borsu, A. Lash, C. Brennan, A. Viale, C. Sander, M. Ladanyi, K. Hoadley, S. Meng, Y. Du, Yufeng Shi, Lulin Li, Y. Turman, D. Zang, E. Helms, S. Balu, X. Zhou, Jinhua Wu, M. D. Topal, D. Hayes, C. Perou, Jun Zhang, Chaowei Wu, S. Shukla, A. Sivachenko, R. Jing, Yueh-Feng Liu, M. Noble, H. Carter, D. Kim, R. Karchin, J. Korkola, Laura M. Heiser, R. Cho, Zhihao Hu, E. Cerami, A. Olshen, B. Reva, Yevgeniy Antipin, R. Shen, P. Mankoo, R. Sheridan, G. Ciriello, William K. Chang, J. Bernanke, D. Haussler, C. Benz, Joshua M. Stuart, S. Benz, J. Z. Sanborn, Charles J. Vaske, Jiangyu Zhu, C. Szeto, G. Scott, C. Yau, M. Wilkerson, N. Zhang, Rehan Akbani, K. Baggerly, W. Yung, J. Weinstein, T. Shelton, D. Grimm, M. Hatfield, S. Morris, P. Yena, P. Rhodes, M. Sherman, J. Paulauskis, S. Millis, A. Kahn, J. Greene, R. Sfeir, M. Jensen, James K. Chen, J. Whitmore, S. Alonso, J. Jordan, A. Chu, Jinghui Zhang, A. Barker, C. Compton, G. Eley, M. Ferguson, P. Fielding, D. Gerhard, R. Myles, C. Schaefer, K. Shaw, J. Vaught, J. Vockley, P. Good, M. Guyer, B. Ozenberger, James Peterson, E. Thomson   +261 more
semanticscholar   +1 more source

Advances in immunotherapy for hepatocellular carcinoma

Nature reviews: Gastroenterology & hepatology, 2021
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs ...
B. Sangro, P. Sarobe, S. Hervás-Stubbs, I. Melero   +3 more
semanticscholar   +1 more source

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source

High Interleukin-6, Low Cd4+ and Cd8+ T-lymphocytes Expressions as Risk Factors of Cervical Carsinoma Infected by Human Papilloma Virus Type-52 [PDF]

, 2013
In Indonesia cervical carcinoma is the most common cancer in women and one of the leading cause of mortality. High risk human papillomavirus (HPV) is the major risk factor of cervical cancer.
Alit-Artha, A. I. (and), Joewarini, E. (E), Mahendra-Dewi, I. G. (I), Suwiyoga, I. K. (I)   +3 more
core  

DACH1 suppresses breast cancer as a negative regulator of CD44. [PDF]

, 2017
Dachshund homolog 1 (DACH1), a key cell fate determination factor, contributes to tumorigenesis, invasion, metastasis of human breast neoplasm. However, the exact molecular mechanisms for the anti-tumor roles of DACH1 in breast carcinoma are still lack ...
Kuang, Dong, Pestell, Richard, Wu, Kongming, Xiong, Jing, Xu, Hanxiao, Yu, Shengnan, Yuan, Xun   +6 more
core   +2 more sources

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

New England Journal of Medicine, 2018
BACKGROUND Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the ...
G. Abou-Alfa, T. Meyer, A. Cheng, A. El-Khoueiry, L. Rimassa, B. Ryoo, I. Çiçin, P. Merle, Yen-Chang Chen, Joong-Won Park, J. Blanc, L. Bolondi, H. Klümpen, S. Chan, V. Zagonel, T. Pressiani, M. Ryu, A. Venook, C. Hessel, A. Borgman-Hagey, G. Schwab, R. Kelley   +21 more
semanticscholar   +1 more source

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

New England Journal of Medicine, 2021
BACKGROUND Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS In this phase 2,
E. Jonasch, F. Donskov, O. Iliopoulos, W. Rathmell, V. Narayan, B. Maughan, S. Oudard, T. Else, J. Maranchie, S. Welsh, S. Thamake, E. Park, R. Perini, W. Linehan, R. Srinivasan   +14 more
semanticscholar   +1 more source

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

Molecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas   +20 more
wiley   +1 more source

Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma

Frontiers in Oncology, 2020
BackgroundTo compare the efficacy of induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus induction chemotherapy plus radiotherapy (IC+RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).Patients and ...
Sai-Lan Liu, Sai-Lan Liu, Xue-Song Sun, Xue-Song Sun, Zi-Jian Lu, Zi-Jian Lu, Qiu-Yan Chen, Qiu-Yan Chen, Huan-Xin Lin, Huan-Xin Lin, Lin-Quan Tang, Lin-Quan Tang, Jin-Xin Bei, Ling Guo, Ling Guo, Hai-Qiang Mai, Hai-Qiang Mai   +16 more
doaj   +1 more source